**Supplementary Fig. 7** Composition, functionality and AdoR expression in TILs.(**a**) Proportion of CD4+ and CD8+ T cells in REP expanded TILs derived from normal/inflamed or tumor prostate tissue and metastasis of colon cancer or of melanoma. (**b**) Cumulative data of the frequency of cytokine-producing or CD107+ CD8+ TILs. Each dot represents a patient, lines indicate Mean±SEM; *n* = 1. (**c**) Cumulative data of the fold change in IL-2, TNF-α production and CD107 expression by TILs stimulated overnight with autologous tumor cells in presence of Ado or ZM 241385+Ado or PSB 1115+Ado. Each dot represents a patient, lines indicate Mean±SEM; *n* = 14. \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001, \*\*\*\**P* < 0.0001, one-way ANOVA test. (**d**) Cumulative data of the expression of AdoR in peripheral T cells from healthy donors and in TILs derived from the depicted tissue types. The 25th to 75th percentiles, the median and min-max of the values are represented by boxes. Each dot represents a patient. The positivity threshold is determined as 2 log higher expression than values given by water. (**e**) Cumulative data of the expression of AdoR in peripheral CD8+ T cells from healthy donors at day 0 or after 3 and 10 days stimulation with anti-CD3/anti-CD28 coated beads. Each dot represents the mean of 8 healthy donors analyzed. \**P* < 0.05, one-way ANOVA test. (**f**) Correlation between the A2AR and HIF-1α expression measured by qRT-PCR in TILs. Spearman test, *n* = 13.